Eli Lilly (LLY) closed the most recent trading day at $771.75, moving -3.45% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.4%. Meanwhile, the Dow ...

Thrive Health Solutions also faces a lawsuit from drugmaker Eli Lilly, for allegedly making false claims about FDA approval when selling compounded version of tirzepatide.

For adults with obesity treated with once-weekly tirzepatide, cardiometabolic risk factor improvements were positively ...

Lilly Endowment Community Scholarship application is now available in Carroll County through the. The Lilly Endowment Community Scholarship Program (LECSP) will provide 147 scholarships ...

A new multi-million dollar grant from the Eli Lilly and Company Foundation will help support a new initiative that aims to increase STEM engagement, achievement and career ...

Eli Lilly's LLY -0.28% Get Free Report short percent of float has fallen 3.96% since its last report. The company recently reported that it has 7.71 million shares sold short, which is 0.97% of all ...

Connecticut passed a new law last week in an effort to lower its spending on weight-loss drugs for its state insurance ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

The Eli Lilly and Company Foundation awarded a multi-year grant of up to $5.5 million to the Indianapolis Public Schools (IPS ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction.

Endometrial Cancer is a type of cancer that begins in the lining of the uterus, most commonly affecting postmenopausal women. Rising prevalence due to increasing obesity rates and aging population, ...